Ownership research and analyst forecasts data provide insight into stock opportunities. Institutions own 49% of Voyager Therapeutics, indicating strong potential. Hedge funds and Neurocrine Biosciences are major shareholders, influencing stock performance. Analyst recommendations and insider ownership are also key factors to consider.